Mease, Philip J.
Orbai, Ana-Maria
FitzGerald, Oliver
Bedaiwi, Mohamed
Dona L. Fleishaker,
Mundayat, Rajiv
Young, Pamela
Helliwell, Philip S.
Funding for this research was provided by:
Pfizer
Article History
Received: 10 November 2022
Accepted: 5 July 2023
First Online: 22 August 2023
Declarations
:
: OPAL Broaden and OPAL Beyond were conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. The study protocols were reviewed and approved by the Institutional Review Boards and/or an Independent Ethics Committee at each study center, and all patients provided written, informed consent.
: Not appliable.
: P. J. Mease has received grant/research support from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer Inc, Sun, and UCB; is a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer Inc, Sun, and UCB; and has been on speakers’ bureaus for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Janssen, Novartis, Pfizer Inc, and UCB. A-M. Orbai has received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Horizon, Janssen, and Novartis; and has received consulting fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer Inc, Sanofi, and UCB. O. FitzGerald has received research grants from AbbVie, Bristol Myers Squibb, Eli Lilly, Novartis, and Pfizer Inc, has received consulting fees from Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, and Pfizer Inc, and has been on speakers’ bureaus for AbbVie, Janssen, and Pfizer Inc. M. Bedaiwi has been on speakers’ bureaus for AbbVie and Pfizer Inc. D. L. Fleishaker, R. Mundayat, and P. Young are employees and shareholders of Pfizer Inc. P. S. Helliwell is a consultant for Eli Lilly and has received fees for educational services from Janssen, Novartis, and Pfizer Inc.